Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND

Indianapolis, IN – July 13, 2017 – Apexian Pharmaceuticals, a clinical stage biotechnology company developing novel compounds to treat cancer, today announced that it has received FDA agreement that the currently approved IND can be used to examine Chemotherapy Induced Peripheral Neuropathy (CIPN) as an indication in addition to its anti-tumor effects. APX3330, the lead molecule for Apexian has a dual biological role through the … Read more…

Apexian Pharmaceuticals licenses IU discoveries

INDIANAPOLIS, IN— Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all technology discovered in Mark Kelley’s laboratory at the Indiana University School of Medicine. Read story on Indiana University website Indiana University Research and Technology Corp., which protects, markets and licenses intellectual property developed at IU so it can be commercialized by industry, issued the license. It allows … Read more…